Search Results - "Stockler, M"

Preferences for cancer treatments: an overview of methods and applications in oncology by Blinman, P., King, M., Norman, R., Viney, R., Stockler, M.R.

“…This review provides cancer clinicians and researchers with an overview of methods for assessing preferences, with examples and recommendations for their…”
Get full text

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer by Lin, H-M, Castillo, L, Mahon, K L, Chiam, K, Lee, B Y, Nguyen, Q, Boyer, M J, Stockler, M R, Pavlakis, N, Marx, G, Mallesara, G, Gurney, H, Clark, S J, Swarbrick, A, Daly, R J, Horvath, L G

“…Background: Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite…”
Get full text

Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial by Grimison, P., Mersiades, A., Kirby, A., Lintzeris, N., Morton, R., Haber, P., Olver, I., Walsh, A., McGregor, I., Cheung, Y., Tognela, A., Hahn, C., Briscoe, K., Aghmesheh, M., Fox, P., Abdi, E., Clarke, S., Della-Fiorentina, S., Shannon, J., Gedye, C., Begbie, S., Simes, J., Stockler, M.

“…This multicentre, randomised, double-blinded, placebo-controlled, phase II/III trial aimed to evaluate an oral THC:CBD (tetrahydrocannabinol:cannabidiol)…”
Get full text

Bisphosphonates for breast cancer by Pavlakis, N, Schmidt, Rl, Stockler, M

“…Bone is the most common site of metastatic disease associated with breast cancer affecting more than half of women during the course of their disease. Bone…”
Get more information

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer by Mahon, K L, Qu, W, Devaney, J, Paul, C, Castillo, L, Wykes, R J, Chatfield, M D, Boyer, M J, Stockler, M R, Marx, G, Gurney, H, Mallesara, G, Molloy, P L, Horvath, L G, Clark, S J

“…Background: Glutathione S-transferase 1 (GSTP1) inactivation is associated with CpG island promoter hypermethylation in the majority of prostate cancers (PCs)…”
Get full text

Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients by Smith-Uffen, M. E. S., Johnson, S. B., Martin, A. J., Tattersall, M. H. N., Stockler, M. R., Bell, M. L., Detering, K., Clayton, J. M., Silvester, W., Clarke, S., Vaccaro, L., Beale, P., Kiely, B. E.

“…Purpose To compare estimates of expected survival time (EST) made by patients with advanced cancer and their oncologists. Methods At enrolment patients…”
Get full text

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29 by Laurie, S.A, Solomon, B.J, Seymour, L, Ellis, P.M, Goss, G.D, Shepherd, F.A, Boyer, M.J, Arnold, A.M, Clingan, P, Laberge, F, Fenton, D, Hirsh, V, Zukin, M, Stockler, M.R, Lee, C.W, Chen, E.X, Montenegro, A, Ding, K, Bradbury, P.A

“…Abstract Introduction This randomised double-blind placebo-controlled study evaluated the addition of cediranib, an inhibitor of vascular endothelial growth…”
Get full text

Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials by West, T.A, Kiely, B.E, Stockler, M.R

“…Abstract Background We sought to estimate worst-case, typical and best-case scenarios for survival in men starting systemic therapies for castration resistant…”
Get full text

What do oncologists think patients with incurable cancer should be told about their prognosis? by Vasista, A., Stockler, M.R., Martin, A., Lawrence, N., Kiely, B.E.

Get full text

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy by Roncolato, F.T., Gibbs, E., Lee, C.K., Asher, R., Davies, L.C., Gebski, V.J., Friedlander, M., Hilpert, F., Wenzel, L., Stockler, M.R., King, M., Pujade-Lauraine, E.

“…Women with platinum-resistant ovarian cancer are a heterogeneous group whose median overall survival is 12 months. We hypothesized that their quality of life…”
Get full text

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS) by Roncolato, F.T., O'Connell, R.L., Joly, F., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Salutari, V., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J., Fehm, T., Ledermann, J., Roemer-Becuwe, C., Stockler, M.R., King, M.T., Friedlander, M.L.

“…Potentially platinum sensitive recurrent ovarian cancer (PPS ROC) is defined by a platinum-free interval of >6 months, and usually treated with platinum-based…”
Get full text

Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer by Schofield, Penelope E., Stockler, M. R., Zannino, D., Tebbutt, N. C., Price, T. J., Simes, R. J., Wong, N., Pavlakis, N., Ransom, D., Moylan, E., Underhill, C., Wyld, D., Burns, I., Ward, R., Wilcken, N., Jefford, M.

“…Purpose Psychological responses to cancer are widely believed to affect survival. We investigated associations between hope, optimism, anxiety, depression,…”
Get full text

Third consensus on medical treatment of metastatic breast cancer by Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C. C., Zwierzina, H.

“…Background: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care…”
Get full text

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial by Tebbutt, N C, Cummins, M M, Sourjina, T, Strickland, A, Van Hazel, G, Ganju, V, Gibbs, D, Stockler, M, Gebski, V, Zalcberg, J

“…Background: Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to better survival than does standard therapy in patients with…”
Get full text

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer by Mahon, K L, Lin, H-M, Castillo, L, Lee, B Y, Lee-Ng, M, Chatfield, M D, Chiam, K, Breit, S N, Brown, D A, Molloy, M P, Marx, G M, Pavlakis, N, Boyer, M J, Stockler, M R, Daly, R J, Henshall, S M, Horvath, L G

“…Background: Docetaxel improves symptoms and survival in metastatic castration-resistant prostate cancer (CRPC). However, ∼50% of patients are chemoresistant…”
Get full text

A systematic review and meta‐analysis of utility estimates in melanoma by Tran, A.D., Fogarty, G., Nowak, A.K., Espinoza, D., Rowbotham, N., Stockler, M.R., Morton, R.L.

“…Summary Background Health‐related quality of life (HRQOL) in melanoma is affected by cancer stage. Previous studies have reported limited data on utility‐based…”
Get full text

Bisphosphonates for breast cancer by Pavlakis, N, Stockler, M

“…Bone is the most common site of metastatic disease associated with breast cancer, and affects more than half of women during the course of their disease. Bone…”
Get more information

Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study by Zhang, A Y, Judson, I, Benson, C, Wunder, J S, Ray-Coquard, I, Grimer, R J, Quek, R, Wong, E, Miah, A B, Ferguson, P C, Dufresne, A, Teh, J Y H, Stockler, M, Tattersall, M H N

“…Background: An increasing number and proportion of cancer patients with apparently localised disease are treated with chemotherapy and radiation therapy in…”
Get full text

Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? by Blinman, P.L., Davis, I.D., Martin, A., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Ritchie, A., Meade, A., Eisen, T., Stockler, M.R.

“…We sought to determine the survival benefits that patients judged sufficient to warrant adjuvant therapy with sorafenib for 1 year, or for 3 years after…”
Get full text

e‐TC: Development and pilot testing of a web‐based intervention to reduce anxiety and depression in survivors of testicular cancer by Heiniger, L.E., Smith, A.B., Olver, I., Grimison, P., Klein, B., Wootten, A., Abbott, J.‐A.M., Price, M.A., McJannett, M., Tran, B., Stockler, M.R., Gurney, H., Butow, P.N.

“…e‐TC is an online intervention designed to address common psychosocial concerns of testicular cancer survivors. It aims to reduce anxiety, depression and fear…”
Get full text